<DOC>
	<DOCNO>NCT00087867</DOCNO>
	<brief_summary>The main objective study assess efficacy SCIOS-469 monotherapy relapse , refractory patient multiple myeloma ( MM ) , base response rate .</brief_summary>
	<brief_title>Study Oral SCIO-469 Relapsed , Refractory Patients With Multiple Myeloma</brief_title>
	<detailed_description>The main objective study assess efficacy SCIO-469 monotherapy relapse , refractory patient multiple myeloma ( MM ) , base response rate . Patients take SCIO-469 two capsule ( 60 mg ) mouth three time day water , preferably meal , 72 day except Days 1 30 monotherapy Days 1 11 combination therapy . On day , second dose SCIO-469 administer collection 12-hour PK sample , third dose administer .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Life expectancy three month diagnose multiple myeloma ( MM ) relapse follow response conventional MM therapy , refractory recent MM therapy Karnofsky performance status = 60 electrocardiographic evidence acute ischemia new conduction system abnormalities history myocardial infarction within last 6 month serum concentration aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = 3X upper limit normal ( ULN ) total serum bilirubin = 2X ULN Calculated measure creatinine clearance &gt; 30 mL/min platelet count = 30 x 10 ( 9 ) /L hemoglobin concentration = 8 g/dL white blood cell count = 2.0 x 10 ( 9 ) /L Patients nonsecretory myeloma , plasma cell leukemia , POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , Mprotein skin change ) major surgery within four week enrollment severe elevate serum calcium heart failure receipt chemotherapy within 21 day enrollment , receive immunotherapy , radiation therapy , investigational agent receipt corticosteroid equivalent 10 mg/day prednisone within two week enrollment known allergy agent use bortezomib ( e.g. , boron mannitol ) poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>SCIO-469</keyword>
	<keyword>p38 MAP kinase</keyword>
	<keyword>myeloma</keyword>
	<keyword>bone marrow</keyword>
</DOC>